Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Erlösung aus Prägung
Renz M. Erlösung aus Prägung - Ein neues Verständnis von Heilung. Psychologie und Theologie im Gespräch. Paderborn: Junfermann, 2017. ISBN 978-3-95571-406-2.
Jan 1, 2017Erlösung aus Prägung
Jan 1, 2017Junfermann, ISBN 978-3-95571-406-2
Renz Monika
Wissenschaft auf den Punkt gebracht
Renz M. Wissenschaft auf den Punkt gebracht - Sterben als Übergang. Psychotherapie & Seelsorge 2017; Themenheft: Denkräume
Jan 1, 2017Wissenschaft auf den Punkt gebracht
Jan 1, 2017Psychotherapie & Seelsorge 2017; Themenheft: Denkräume
Renz Monika
In der Frage bleiben
Renz M. In der Frage bleiben - Aufgezeichnet und fotografiert von C. Klein. Ferment 2017; Bildband:28-31.
Jan 1, 2017In der Frage bleiben
Jan 1, 2017Ferment 2017; Bildband:28-31
Renz Monika
Hinübergehen
Renz M. Hinübergehen - Was beim Sterben geschieht. Annäherungen an letzte Wahrheiten unseres Lebens. Basel: Herder, 2017. ISBN 978-3-451-06788-4.
Jan 1, 2017Hinübergehen
Jan 1, 2017Herder, ISBN 978-3-451-06788-4
Renz Monika
Eo tteoh ge jug eum eul ma ju hal geos in ga [Hinübergehen]
Renz M. Eo tteoh ge jug eum eul ma ju hal geos in ga [Hinübergehen] - a leum da un ma mu li leul wi han im jong hag gang ui. Seoul: Chaek-Se-Sang Pub. Co., 2017. ISBN 979-11-5931-110-9.
Jan 1, 2017Eo tteoh ge jug eum eul ma ju hal geos in ga [Hinübergehen]
Jan 1, 2017Chaek-Se-Sang Pub. Co., ISBN 979-11-5931-110-9
Renz Monika
Slit2/Robo4 Signaling: Potential Role of a VEGF-Antagonist Pathway to Regulate Luteal Permeability
Bekes I, Haunerdinger V, Sauter R, Holzheu I, Janni W, Wöckel A, Wulff C. Slit2/Robo4 Signaling: Potential Role of a VEGF-Antagonist Pathway to Regulate Luteal Permeability. Geburtshilfe Frauenheilkd 2017; 77:73-80.
Jan 1, 2017Slit2/Robo4 Signaling: Potential Role of a VEGF-Antagonist Pathway to Regulate Luteal Permeability
Jan 1, 2017Geburtshilfe Frauenheilkd 2017; 77:73-80
Bekes Inga, Haunerdinger V, Sauter R, Holzheu I, Janni W, Wöckel A, Wulff C
Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression
Nitz U, Weiss E, Böhmer S, Kreienberg R, du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Hoffmann G, Augustin D, Möbus V, Gluz O, Huober J, Kreipe H, Kates R, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Kuhn W. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. Ann Oncol 2017; 28:2899.
Jan 1, 2017Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression
Jan 1, 2017Ann Oncol 2017; 28:2899
Nitz U, Weiss E, Böhmer S, Kreienberg R, du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Hoffmann G, Augustin D, Möbus V, Gluz O, Huober Jens, Kreipe H H, Kates R E, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Kuhn W
Neuer Therapieansatz mit Denosumab bei Riesenzellgranulomen. Ein Fallbeispiel.
Rostetter C, Rordorf T, Essig H, Zweifel D, Schumann P, Rücker M, Bredell M. Neuer Therapieansatz mit Denosumab bei Riesenzellgranulomen. Ein Fallbeispiel. Swiss Dent J 2017; 127:520-521.
Jan 1, 2017Neuer Therapieansatz mit Denosumab bei Riesenzellgranulomen. Ein Fallbeispiel.
Jan 1, 2017Swiss Dent J 2017; 127:520-521
Rostetter Claudio, Rordorf Tamara, Essig Harald, Zweifel Daniel F, Schumann Paul, Rücker Martin, Bredell Marius
Spontaneous multifocal cervical liquor leakage causing an intracranial hypotension syndrome
Hundsberger T (2016). Spontaneous multifocal cervical liquor leakage causing an intracranial hypotension syndrome.
Dec 30, 2016Spontaneous multifocal cervical liquor leakage causing an intracranial hypotension syndrome
Dec 30, 2016Gemeinsame Jahrestagung der Schweizerischen Neurologischen Gesellschaft (178. Tagung) und der Schweizerischen Gesellschaft für Klinische Neurophysiologie und SVEPTA Fortbildung
Hundsberger Thomas
Thyroid Abnormalities following the use of CTLA-4 and PD-1 Inhibitors in the treatment of melanoma
Diem S. Thyroid Abnormalities following the use of CTLA-4 and PD-1 Inhibitors in the treatment of melanoma. Clinical endocrinology 2016
Dec 29, 2016Thyroid Abnormalities following the use of CTLA-4 and PD-1 Inhibitors in the treatment of melanoma
Dec 29, 2016Clinical endocrinology 2016
Diem Stefan
Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies
Meulendijks D, Rozeman E, Cats A, Sikorska K, Jörger M, Deenen M, Beijnen J, Schellens J. Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies. Pharmacogenomics J 2016
Dec 20, 2016Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies
Dec 20, 2016Pharmacogenomics J 2016
Meulendijks D, Rozeman E A, Cats A, Sikorska K, Jörger Markus, Deenen M J, Beijnen J H, Schellens J H M
Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99
Pagani O, Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann B, Moos R, Zaman K, Goldhirsch A, Pestalozzi B, Munzone E, Klingbiel D, Ruhstaller T, Nolé F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess D, Mamot C. Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99. Ann Oncol 2016
Dec 19, 2016Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99
Dec 19, 2016Ann Oncol 2016
Pagani O, Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann Beat, Moos R von, Zaman K, Goldhirsch A, Pestalozzi B, Munzone E, Klingbiel D, Ruhstaller Thomas, Nolé F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess Dagmar, Mamot C
Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)
Schmid S, Diebold J, Jochum W, Reichegger H, Klingbiel D, Froesch P, Mark M, Rothschild S, Gautschi O, Früh M. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs). J Thorac Oncol 2016
Dec 19, 2016Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)
Dec 19, 2016J Thorac Oncol 2016
Schmid Sabine, Diebold Joachim, Jochum Wolfram, Reichegger Hermann, Klingbiel Dirk, Froesch Patrizia, Mark Michael, Rothschild Sacha, Gautschi Oliver, Früh Martin
Autologous hematopoietic stem cell transplantation for intravascular large B-cell lymphoma: the European Society for Blood and Marrow Transplantation experience
Meissner J, Montoto S, Samaras P, Robinson S, Pioltelli P, Pabst T, Mohty M, Ludwig H, Hess U, Finke J, Delage J, Cornelissen J, Abecasis M, Laboure G, Kanfer E, Boumendil A, Dietrich S, Finel H, Dreger P. Autologous hematopoietic stem cell transplantation for intravascular large B-cell lymphoma: the European Society for Blood and Marrow Transplantation experience. Bone Marrow Transplant 2016; 52:650-652.
Dec 19, 2016Autologous hematopoietic stem cell transplantation for intravascular large B-cell lymphoma: the European Society for Blood and Marrow Transplantation experience
Dec 19, 2016Bone Marrow Transplant 2016; 52:650-652
Meissner J, Montoto S, Samaras P, Robinson S, Pioltelli P, Pabst T, Mohty M, Ludwig H, Hess Urs, Finke J, Delage J, Cornelissen J, Abecasis M, Laboure G, Kanfer E, Boumendil A, Dietrich S, Finel H, Dreger P
Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2(nd) -line therapy for relapsed and refractory multiple myeloma - a phase II trial
Mey U, Ruefer A, Ziske C, Knauf W, Cathomas R, von Moos R, Hitz F, Sauter R, Hiendlmeyer E, Cantoni N, Bargetzi M, Fischer N, Doerfel S, Brugger W, Schwarb H, Pederiva S, Schwarzer A, Dechow T, Jehner P, Rauh J, Taverna C, Schmid M, Schmidt-Hieber M, Driessen C. Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2(nd) -line therapy for relapsed and refractory multiple myeloma - a phase II trial. Br J Haematol 2016
Dec 16, 2016Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2(nd) -line therapy for relapsed and refractory multiple myeloma - a phase II trial
Dec 16, 2016Br J Haematol 2016
Mey Ulrich J M, Ruefer Axel, Ziske Carsten, Knauf Wolfgang, Cathomas Richard, von Moos Roger, Hitz Felicitas, Sauter Rafael, Hiendlmeyer Elke, Cantoni Nathan, Bargetzi Mario, Fischer Natalie, Doerfel Steffen, Brugger Wolfram, Schwarb Heike, Pederiva Stefanie, Schwarzer Andreas, Dechow Tobias, Jehner Paul, Rauh Jacqueline, Taverna Christian J, Schmid Mathias, Schmidt-Hieber Martin, Driessen Christoph
Diagnostischer Stellenwert der Nervensonographie beim Karpaltunnelsyndrom
Hundsberger T. Diagnostischer Stellenwert der Nervensonographie beim Karpaltunnelsyndrom - Nervenengpasssyndrom. InFo Neurologie & Psychiatrie 2016; 14:12-15.
Nov 30, 2016Diagnostischer Stellenwert der Nervensonographie beim Karpaltunnelsyndrom
Nov 30, 2016InFo Neurologie & Psychiatrie 2016; 14:12-15
Hundsberger Thomas
Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma
Fischer S, Cohn-Cedermark G, Ståhl O, Chau C, Arriola E, Marti K, Hutton P, Laguerre B, Maroto P, Beyer J, Dieckmann K, Lorch A, Tandstad T, Wheater M, Porfiri E, Flechon A, Aparicio J, Klingbiel D, Skrbinc B, Basso U, Shamash J, Gillessen Sommer S. Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma. J Clin Oncol 2016; 35:194-200.
Nov 28, 2016Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma
Nov 28, 2016J Clin Oncol 2016; 35:194-200
Fischer Stefanie, Cohn-Cedermark Gabriella, Ståhl Olof, Chau Caroline, Arriola Edurne, Marti Kalena, Hutton Paul, Laguerre Brigitte, Maroto Pablo, Beyer Jörg, Dieckmann Klaus-Peter, Lorch Anja, Tandstad Torgrim, Wheater Matthew, Porfiri Emilio, Flechon Aude, Aparicio Jorge, Klingbiel Dirk, Skrbinc Breda, Basso Umberto, Shamash Jonathan, Gillessen Sommer Silke
Comparison of three or fewer high-dose chemotherapy cycles as salvage treatment in germ cell tumors in first relapse
Gössi F, Schardt J, Bargetzi M, Berthold D, Hess U, Stenner F, Mischo A, Panagiotis S, Zweifel M, Spahn M, Pabst T. Comparison of three or fewer high-dose chemotherapy cycles as salvage treatment in germ cell tumors in first relapse. Bone Marrow Transplant 2016; 52:334-336.
Nov 28, 2016Comparison of three or fewer high-dose chemotherapy cycles as salvage treatment in germ cell tumors in first relapse
Nov 28, 2016Bone Marrow Transplant 2016; 52:334-336
Gössi F, Schardt J, Bargetzi M, Berthold D, Hess Urs, Stenner F, Mischo A, Panagiotis S, Zweifel M, Spahn M, Pabst T
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial
Gautschi O, Ochsenbein A, Mach N, Biaggi C, Schneider M, Zander T, Froesch P, Peters S, Pless M, Rauch D, Cathomas R, Stahel R, Früh M, Betticher D, Zippelius A, Matter-Walstra K, Li Q, Rothschild S. Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. Clin Lung Cancer 2016
Nov 23, 2016Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial
Nov 23, 2016Clin Lung Cancer 2016
Gautschi Oliver, Ochsenbein Adrian F, Mach Nicolas, Biaggi Christine, Schneider Martina, Zander Thilo, Froesch Patrizia, Peters Solange, Pless Miklos, Rauch Daniel, Cathomas Richard, Stahel Rolf A, Früh Martin, Betticher Daniel C, Zippelius Alfred, Matter-Walstra Klazien, Li Qiyu, Rothschild Sacha I
Expression of CK19 is an independent predictor of negative outcome for patients with squamous cell carcinoma of the tongue.
Ernst J, Ikenberg K, Apel B, Schumann D, Huber G, Studer G, Rordorf T, Riesterer O, Rössle M, Korol D, Bredell M. Expression of CK19 is an independent predictor of negative outcome for patients with squamous cell carcinoma of the tongue. Oncotarget 2016; 7:76151-76158.
Nov 15, 2016Expression of CK19 is an independent predictor of negative outcome for patients with squamous cell carcinoma of the tongue.
Nov 15, 2016Oncotarget 2016; 7:76151-76158
Ernst Jutta, Ikenberg Kristian, Apel Barbara, Schumann Desiree M, Huber Gerhard, Studer Gabriela, Rordorf Tamara, Riesterer Oliver, Rössle Matthias, Korol Dimitri, Bredell Marius